11. Biosimilars for psoriasis: clinical studies to determine similarity. (28th May 2017) Authors: Blauvelt, A.; Puig, L.; Chimenti, S.; Vender, R.; Rajagopalan, M.; Romiti, R.; Skov, L.; Zachariae, C.; Young, H.; Prens, E.; Cohen, A.; van der Walt, J.; Wu, J.J. Journal: British journal of dermatology Issue: Volume 177:Number 1(2017) Page Start: 23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. (1st February 2016) Authors: Blauvelt, A.; Cohen, A.D.; Puig, L.; Vender, R.; van der Walt, J.; Wu, J.J. Journal: British journal of dermatology Issue: Volume 174:Number 2(2016) Page Start: 282 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. (30th December 2015) Authors: Blauvelt, A.; Cohen, A.D.; Puig, L.; Vender, R.; van der Walt, J.; Wu, J.J. Journal: British journal of dermatology Issue: Volume 174:Number 2(2016) Page Start: 282 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. (1st December 2017) Authors: Cohen, A.D.; Wu, J.J.; Puig, L.; Chimenti, S.; Vender, R.; Rajagopalan, M.; Romiti, R.; de la Cruz, C.; Skov, L.; Zachariae, C.; Young, H.S.; Foley, P.; van der Walt, J.M.; Naldi, L.; Prens, E.P.; Blauvelt, A. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1495 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. (27th November 2017) Authors: Cohen, A.D.; Wu, J.J.; Puig, L.; Chimenti, S.; Vender, R.; Rajagopalan, M.; Romiti, R.; de la Cruz, C.; Skov, L.; Zachariae, C.; Young, H.S.; Foley, P.; van der Walt, J.M.; Naldi, L.; Prens, E.P.; Blauvelt, A. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1495 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. (27th November 2017) Authors: Cohen, A.D.; Wu, J.J.; Puig, L.; Chimenti, S.; Vender, R.; Rajagopalan, M.; Romiti, R.; de la Cruz, C.; Skov, L.; Zachariae, C.; Young, H.S.; Foley, P.; van der Walt, J.M.; Naldi, L.; Prens, E.P.; Blauvelt, A. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1495 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis. (7th September 2016) Authors: Griffiths, C.E.M.; Vender, R.; Sofen, H.; Kircik, L.; Tan, H.; Rottinghaus, S.T.; Bachinsky, M.; Mallbris, L.; Mamolo, C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 31:Number 2(2017) Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab. (20th January 2015) Authors: Bissonnette, R.; Maari, C.; Barber, K.; Lynde, C.W.; Vender, R. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 8(2015:Aug.) Page Start: 1576 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody. (2nd November 2018) Authors: Papp, K.A.; Gooderham, M.; Jenkins, R.; Vender, R.; Szepietowski, J.C.; Wagner, T.; Hunt, B.; Souberbielle, B. Journal: British journal of dermatology Issue: Volume 180:Number 6(2019) Page Start: 1352 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody. (1st June 2019) Authors: Papp, K.A.; Gooderham, M.; Jenkins, R.; Vender, R.; Szepietowski, J.C.; Wagner, T.; Hunt, B.; Souberbielle, B. Journal: British journal of dermatology Issue: Volume 180:Number 6(2019) Page Start: 1352 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗